Is Dapagliflozin More Than Just Another Oral Diabetes Drug?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and AstraZeneca's novel, oral SGLT-2 inhibitor dapagliflozin met the endpoints in a Phase III study as an add-on to metformin. But some question whether the results are robust enough for the drug to make it in the highly competitive diabetes market